Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-11-15 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2018年第六次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2018年第六次临时股东大会" (2018 Sixth Extraordinary General Meeting) of KPC Pharmaceuticals, Inc. It contains detailed meeting agenda, voting procedures, and multiple proposals related to the use of idle funds, cash management of raised funds, and project completion with surplus funds allocation. The content is focused on the meeting materials for a shareholders' meeting, including explanations of proposals and voting methods, rather than the results of the vote or a summary announcement. It is not a report of voting results (DVA), nor is it a proxy solicitation (PSI) or a report publication announcement (RPA). It is clearly a set of meeting materials provided to shareholders for the Extraordinary General Meeting (EGM). The closest category is AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or other shareholders' meetings. Given the detailed nature and purpose, the document fits best as AGM Information (AGM-R).
2018-11-15 Chinese
独立董事关于公司使用部分闲置募集资金进行现金管理的议案的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on the company's proposal to use part of idle raised funds for cash management. It references regulatory guidelines and confirms compliance and approval. This is a governance-related statement concerning the use of raised capital but does not contain financial statements or detailed financial results. It is not an annual report, audit report, or earnings release. It is also not a report publication announcement or a certification letter. The content fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related announcement that does not fit other specific categories.
2018-11-09 Chinese
独立董事关于公司利用闲置自有资金进行投资理财业务的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of Kunming Pharmaceutical Corporation regarding the company's plan to use idle funds for investment and financial management. It references regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is a formal opinion or certification related to a specific company action rather than a full report or announcement of results. It is not an annual report, interim report, earnings release, or any other detailed financial filing. Given its nature as an independent directors' opinion on a specific matter, it fits best under Regulatory Filings (RNS), which covers attestations, certifications, and miscellaneous regulatory documents that do not fit other categories.
2018-11-09 Chinese
独立董事关于公司部分募集资金投资项目结项并将结余募集资金永久补充流动资金的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the completion of certain fundraising investment projects and the permanent replenishment of surplus raised funds into working capital. It references compliance with regulatory guidelines and stock exchange rules related to fundraising management. The document is short (514 characters) and serves as an opinion or certification rather than a full financial report or announcement of voting results. It does not contain financial statements or detailed financial data. This type of document is best classified as a Regulatory Filing (RNS) because it is a compliance-related statement by independent directors regarding fundraising use, not a full report or announcement of voting results.
2018-11-09 Chinese
九届二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the second meeting of the ninth board of directors of Kunming Pharmaceutical Corporation (昆药集团股份有限公司). It includes multiple investment projects, strategic decisions, and approvals by the board, such as ERP system implementation, investment in a new drug development project, overseas medical service projects, and research institute construction. The document is a formal board meeting resolution announcement, not a full annual report, audit report, or financial statement. It does not contain financial results or earnings data, nor is it a transcript or presentation. It is clearly a Board/Management Information filing announcing board decisions and management resolutions. The document length (7176 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive board resolution announcement.
2018-11-08 Chinese
东海证券股份有限公司关于昆药集团股份有限公司部分募集资金投资项目结项并将结余募集资金永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Donghai Securities regarding the completion of certain fundraising investment projects by Kunming Pharmaceutical Group Co., Ltd. and the permanent supplementation of surplus raised funds into working capital. It includes specifics about the fundraising amount, project changes, usage, surplus funds, and compliance with regulatory requirements. The document is not a full financial report but rather a verification or audit opinion related to the use of raised funds. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not an announcement of a report but a standalone audit-related document. Therefore, it fits the category of an Audit Report / Information (AR). The document length (2667 characters) and content support this classification with high confidence. FY 2018
2018-11-08 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.